Long, Smith, Quinn named to new positions at Roswell Park

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Mary Ann Long
Laurie J. Smith
Timothy Quinn

Three leaders were appointed to Roswell Park Comprehensive Cancer Center:

  • Mary Ann Long was named senior vice president of nursing. Long will focus on evaluating service in inpatient, outpatient and community practices, and will provide leadership to all nursing teams across the center.
    Long was previously director of Magnet at Roswell Park until her retirement in 2012, and also served as assistant director of nursing and director of patient care services, in addition to more than 30 years of service as an intensive care unit nurse.

  • Laurie J. Smith was named vice president of clinical research services. As vice president, Smith will support more than 400 active clinical trials a year and supervise staff engaged in study submission, study implementation, data collection and management.
    Smith previously served as an independent consultant and, prior to that, as vice president of clinical research for AMITA Health in Chicago.
  • Timothy Quinn was named chief of critical care. Quinn, previously co-director of the Intensive Care Unit, has been named to the newly created role of chief of critical care. He will work with members of Roswell Park’s Intensive Care Unit and Intermediate Care Unit to provide cutting-edge and evidence-based oncologic care to patients. A critical care anesthesiologist at the Center, Quinn’s research interests include preoperative evaluation of high-risk patients, intraoperative care and postoperative quality-improvement initiatives.
Table of Contents

YOU MAY BE INTERESTED IN

On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login